Verschicke keinen generischen Lebenslauf — erstelle einen Lebenslauf und ein Anschreiben, die genau auf diese Rolle zugeschnitten sind.
The German Cancer Research Center (DKFZ) in Heidelberg invites applications for a PhD Student in Immunotherapy/Optical CRISPR Screens/Spatial Transcriptomics. The project focuses on identifying elite anti-tumor T cells using advanced genetic engineering, high‑throughput CRISPR screens, and spatial omics.
You will work across in vitro and in vivo models in collaboration with leading groups. Starting January 2027, the position offers a rich, international research environment with state‑of‑the‑art
The German Cancer Research Center (DKFZ) is one of Europe’s largest cancer research centers. “Research for a life without cancer" is the mission of our world-class scientists and all our team members.
The DKFZ is a place where the brightest minds pursue bold ideas and seek answers to pioneering scientific questions through collaboration, innovation, and exploration across many disciplines. We provide a dynamic environment which empowers excellence with state-of-the-art technologies, cutting edge infrastructure, and a global scientific network.
Contribute your knowledge, vision, and dedication to create a space where scientific discovery in cancer research is transformed into benefits for human health.
For our Junior Research GroupPediatric Immuno-Oncology (led by Dr. Dr. Franziska Blaeschke) we are seeking, starting in January 2027, a
Your group uses advanced genetic engineering and high-throughput CRISPR screens to improve CAR- and TCR-based immunotherapies. This project explores how highly effective anti-tumor immune cells can be identified and enhanced to better fight cancer. By combining functional screening (e.g., genome-wide CRISPR screens), cutting-edge cell engineering (e.g., AAV-based knockins, base editing), and innovative imaging and sequencing technologies (e.g., NIS-seq, spatial transcriptomics/proteomics), we aim to uncover key features of the most powerful anti-tumor T cells (“elite” immune cells) and translate these insights into next-generation immunotherapies.
The work will include a large variety of experimental methods and models (in vitro and in vivo), in close collaboration with the groups of Prof. Dr. Adelheid Cerwenka (Department of Immunobiochemistry, Medical Faculty Mannheim of Heidelberg University), Prof. Dr. Joachim Spatz (Department of Cellular Biophysics, Max Planck Institute), Prof. Dr. Nina Papavasiliou (Division of Immune Diversity, DKFZ), Prof. Dr. Michael Platten (Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology at DKFZ and Department of Neurology at the University Medical Center Mannheim), and Dr. Vibor Laketa (Infectious Diseases Imaging Platform, UKHD). Together, the project seeks to define and build next-generation immune cells with enhanced therapeutic potential.
Dr.FranziskaBlaeschke
Phone:+49 (0)6221/42-1370
The position is initially limited to 3 years.
October 15, 2026
We are convinced that an innovative research and working environment thrives on the diversity of its employees. Therefore, we welcome applications from talented people, regardless of gender, cultural background, nationality, ethnicity, sexual identity, physical ability, religion and age. People with severe disabilities are given preference if they have the same aptitude.
Notice:We are subject to the regulations of the Infection Protection Act (IfSG). Therefore, all our employees must provide proof of immunity against measles.